Breaking News

Adidas to Start EU1.5B Shareholder Return Program
Tweet TWEET

Orion Oyj : Annual Summary of Stock Exchange Releases published in 2012

   Orion Oyj : Annual Summary of Stock Exchange Releases published in 2012

ORION CORPORATION    STOCK EXCHANGE RELEASE 21 JAN 2013 AT 10:00 a.m.EET
      

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market
Act, Orion Corporation publishes an Annual Summary of the stock exchange
releases published by the company in 2012. The releases are available on the
internet website of Orion Corporation, at http://www.orion.fi/se-releases.
Orion points out that part of the information in the releases can have become
out-dated.

Stock Exchange Releases in 2012

January
20 Jan 2012 Orion invites analysts and media to Financial Statement Release
            conference on Tuesday 7 February 2012
20 Jan 2012 Orion Corporation: Annual Summary of Stock Exchange Releases
            published in 2011
30 Jan 2012 Recommendation by the Nomination Committee concerning Board of
            Directors to be elected by the 2012 AGM of Orion Corporation
February
7 Feb 2012  Orion continues development of inhalable budesonide-formoterol
            combined formulation
7 Feb 2012  Orion Group Financial Statement Release for 2011
7 Feb 2012  Notice to the Annual General Meeting of Orion Corporation
March
6 Mar 2012  Orion Group Annual Report 2011 published
12 Mar 2012 Orion Corporation: Transfer of 87,763 own B-shares on 12 March
            2012
20 Mar 2012 Orion Oyj : Decisions by the AGM on 20 March 2012
20 Mar 2012 Orion Oyj : Orion Corporation: Organising meeting of the Board of
            Directors
26 Mar 2012 Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a
            generic version of Orion's proprietary drug Stalevo® in the United
            States
April
10 Apr 2012 Orion Corporation: 300,000 Orion A-shares converted into B-shares
10 Apr 2012 Orion invites analysts and media to Q1 news conference on Tuesday
            24 April 2012
24 Apr 2012 Orion Group Interim Report January-March 2012
26 Apr 2012 Orion sues Mylan in the U.S. to enforce its U.S. patents covering
            the proprietary drug Stalevo®
May
1 May 2012  U.S. District Court gives decision on Precedex® patent litigation
June
July
3 Jul 2012  Orion upgrades full-year outlook for 2012
5 Jul 2012  200,000 Orion A-shares converted into B-shares
16 Jul 2012 Orion invites analysts and media to Q2 news conference on Tuesday
            31 July 2012
31 Jul 2012 Orion Corporation's publication schedules for financial reporting
            in 2013
31 Jul 2012 Orion Group Interim Report January-June 2012
August
September
5 Sep 2012  Disclosure Under Chapter 2 Section 10
5 Sep 2012  Orion Corporation: Correction to the English version of the stock
            exchange release
12 Sep 2012 200,000 Orion A-shares converted into B-shares
October
9 Oct 2012  Orion invites analysts and media to Q3 news conference on Tuesday
            23 October 2012
9 Oct 2012  Orion upgrades full-year outlook for 2012
23 Oct 2012 Orion Group Interim Report January-September 2012
23 Oct 2012 Composition of the Nomination Committee of Orion Corporation
November
19 Nov 2012 823,000 Orion A-shares converted into B-shares
30 Nov 2012 Orion is planning to apply for a marketing authorisation for
            combined budesonide-formoterol formulation of the Easyhaler®
            product family
December
20 Dec 2012 203,000 Orion A-shares converted into B-shares
20 Dec 2012 Orion and Mylan settle patent dispute over the proprietary drug
            Comtan®

Orion Corporation

Timo Lappalainen  Olli Huotari
President and CEO SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. Pharmaceutical R&D focuses on central nervous
system drugs, oncology and critical care drugs, and Easyhaler® pulmonary
drugs.



Orion's net sales in 2011 amounted to EUR 918 million and the company had
about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX
Helsinki.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Orion Oyj via Thomson Reuters ONE
HUG#1671690
 
Press spacebar to pause and continue. Press esc to stop.